Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats

References

1. 1.↵
   1. Radbruch A,
   2. Richter H,
   3. Fingerhut S, et al

   . Gadolinium deposition in the brain in a large animal model: comparison of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2019;54:531–36 doi:10.1097/RLI.0000000000000575 pmid:31261291

   CrossRefPubMed
2. 2.↵
   1. Kong Y,
   2. Zhang S,
   3. Wang J, et al

   . Potential toxicity evaluation and comparison within multiple mice organs after repeat injections of linear versus macrocyclic gadolinium-based contrast agents: a comprehensive and time course study. Toxicol Lett 2021;350:152–61 doi:10.1016/j.toxlet.2021.07.016 pmid:34311048

   CrossRefPubMed
3. 3.↵
   1. Robert P,
   2. Violas X,
   3. Grand S, et al

   . Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 2016;51:73–82 doi:10.1097/RLI.0000000000000241 pmid:26606549

   CrossRefPubMed
4. 4.↵
   1. Burke LM,
   2. Ramalho M,
   3. AlObaidy M, et al

   . Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging 2016;34:1078–80 doi:10.1016/j.mri.2016.05.005 pmid:27211256

   CrossRefPubMed
5. 5.↵
   1. Maramattom BV,
   2. Manno EM,
   3. Wijdicks EF, et al

   . Gadolinium encephalopathy in a patient with renal failure. Neurology 2005;64:1276–78 doi:10.1212/01.WNL.0000156805.45547.6E pmid:15824364

   Abstract/FREE Full Text
6. 6.↵
   1. Ray JG,
   2. Vermeulen MJ,
   3. Bharatha A, et al

   . Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316:952–61 doi:10.1001/jama.2016.12126 pmid:27599330

   CrossRefPubMed
7. 7.↵
   1. Semelka RC,
   2. Ramalho M,
   3. AlObaidy M, et al

   . Gadolinium in humans: a family of disorders. AJR Am J Roentgenol 2016;207:229–33 doi:10.2214/AJR.15.15842 pmid:27224028

   CrossRefPubMed
8. 8.↵
   1. Semelka RC,
   2. Ramalho M

   . Gadolinium deposition disease: current state of knowledge and expert opinion. Invest Radiology 2023;58:523–29 doi:10.1097/RLI.0000000000000977 pmid:37058336

   CrossRefPubMed
9. 9.↵
   FDA Center for Drug Evaluation and Research. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. https://www.fda.gov/media/72309/download. 2005. Accessed October 6, 2022
10. 10.↵
    1. Schabel MC,
    2. Parker DL

    . Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol 2008;53:2345–73 doi:10.1088/0031-9155/53/9/010 pmid:18421121

    CrossRefPubMed
11. 11.↵
    1. Schabel MC,
    2. Morrell GR

    . Uncertainty in T(1) mapping using the variable flip angle method with two flip angles. Phys Med Biol 2009;54:N1–N8 doi:10.1088/0031-9155/54/1/N01 pmid:19060359

    CrossRefPubMed
12. 12.↵
    1. Wang ST,
    2. Hua ZX,
    3. Fan DX, et al

    . Gadolinium retention and clearance in the diabetic brain after administrations of gadodiamide, gadopentetate dimeglumine, and gadoterate meglumine in a rat model. Biomed Res Int 2019;2019:3901907 doi:10.1155/2019/3901907 pmid:31192255

    CrossRefPubMed
13. 13.↵
    1. Paxinos G,
    2. Watson C

    . The Rat Brain in Stereotaxic Coordinates. 6th ed. London, UK, Academic Press; 2007
14. 14.↵
    1. Morris R

    . Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47–60 doi:10.1016/0165-0270(84)90007-4 pmid:6471907

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Puig B,
    2. Brenna S,
    3. Magnus T

    . Molecular communication of a dying neuron in stroke. Int J Mol Sci 2018;19:2834 doi:10.3390/ijms19092834

    CrossRefPubMed
16. 16.↵
    1. Kanavaki A,
    2. Spengos K,
    3. Moraki M, et al

    . Serum levels of S100b and NSE proteins in patients with non-transfusion-dependent thalassemia as biomarkers of brain ischemia and cerebral vasculopathy. Int J Mol Sci 2017;18:2724 doi:10.3390/ijms18122724 pmid:29244749

    CrossRefPubMed
17. 17.↵
    1. Tefr Faridová A,
    2. Heřman H,
    3. Danačíková Š, et al

    . Serum biomarkers of hypoxic-ischemic brain injury. Physiol Res 2023;72:S461–74 doi:10.33549/physiolres.935214 pmid:38165751

    CrossRefPubMed
18. 18.↵
    1. Rasschaert M,
    2. Schroeder JA,
    3. Wu TD, et al

    . Multimodal imaging study of gadolinium presence in rat cerebellum: differences between Gd chelates, presence in the Virchow-Robin space: association with lipofuscin, and hypotheses about distribution pathway. Invest Radiol 2018;53:518–28 doi:10.1097/RLI.0000000000000490 pmid:29985204

    CrossRefPubMed
19. 19.↵
    1. Fretellier N,
    2. Granottier A,
    3. Rasschaert M, et al

    . Does age interfere with gadolinium toxicity and presence in brain and bone tissues? A comparative gadoterate versus gadodiamide study in juvenile and adult rats. Invest Radiol 2019;54:61–71 doi:10.1097/RLI.0000000000000517 pmid:30394964

    CrossRefPubMed
20. 20.↵
    1. Lohrke J,
    2. Frisk AL,
    3. Frenzel T, et al

    . Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2017;52:324–33 doi:10.1097/RLI.0000000000000344 pmid:28323657

    CrossRefPubMed
21. 21.↵
    1. Miller JH,
    2. Hu HH,
    3. Pokorney A, et al

    . MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015;136:e1637–40 doi:10.1542/peds.2015-2222 pmid:26574593

    CrossRefPubMed
22. 22.↵
    1. Murata N,
    2. Murata K,
    3. Gonzalez-Cuyar LF, et al

    . Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 2016;34:1359–65 doi:10.1016/j.mri.2016.08.025 pmid:27720805

    CrossRefPubMed
23. 23.↵
    1. Bloomer SA,
    2. Moyer ED,
    3. Brown KE, et al

    . Aging results in accumulation of M1 and M2 hepatic macrophages and a differential response to gadolinium chloride. Histochem Cell Biol 2020;153:37–48 doi:10.1007/s00418-019-01827-y pmid:31691025

    CrossRefPubMed
24. 24.↵
    1. Ishibashi H,
    2. Hirao K,
    3. Yamaguchi J, et al

    . Inhibition of chloride outward transport by gadolinium in cultured rat spinal cord neurons. Neurotoxicology 2009;30:155–59 doi:10.1016/j.neuro.2008.10.003 pmid:19007810

    CrossRefPubMed
25. 25.↵
    1. Ye L,
    2. Shi Z,
    3. Liu H, et al

    . GdCl3 induced Hep G2 cell death through mitochondrial and external death pathways without significant elevation of ROS generation. Biol Trace Elem Res 2013;151:148–55 doi:10.1007/s12011-012-9538-y pmid:23129526

    CrossRefPubMed
26. 26.↵
    1. Lauer M,
    2. Lauer A,
    3. You SJ, et al

    . Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI? Neurosurg Focus 2021;50:E12 doi:10.3171/2020.10.FOCUS20402 pmid:33386012

    CrossRefPubMed
27. 27.↵
    1. Ray DE,
    2. Cavanagh JB,
    3. Nolan CC, et al

    . Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats. AJNR Am J Neuroradiol 1996;17:365–73 pmid:8938312

    PubMed
28. 28.↵
    1. Bertin A,
    2. Michou-Gallani AI,
    3. Gallani JL, et al

    . In vitro neurotoxicity of magnetic resonance imaging (MRI) contrast agents: influence of the molecular structure and paramagnetic ion. Toxicol In Vitro 2010;24:1386–94 doi:10.1016/j.tiv.2010.05.001 pmid:20460148

    CrossRefPubMed
29. 29.↵
    1. Bauer K,
    2. Lathrum A,
    3. Raslan O, et al

    . Do gadolinium-based contrast agents affect 18F-FDG PET/CT uptake in the dentate nucleus and the globus pallidus? A pilot study. J Nucl Med Technol 2017;45:30–33 doi:10.2967/jnmt.116.180844 pmid:27834725

    Abstract/FREE Full Text